<DOC>
	<DOCNO>NCT01549093</DOCNO>
	<brief_summary>The purpose study determine whether Endostar Gemcitabine-Carboplatin effective Gemcitabine-Carboplatin alone treatment Non-Small Cell Lung Cancer ( NSCLC ) , Endostar , Compared intravenous , Continued vein-pumping maby effective way .</brief_summary>
	<brief_title>Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin Treat Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Endostar anti-tumor activity vascular endothelial growth factor initial treatment . This study design evaluate safety efficacy Endostar Continued vein-pumping Combining Gemcitabine-Carboplatin ( GC ) chemotherapy patient NSCLC , seek effective injection . Methods : In randomize , open label , 90 patient plan enrolled random 3 arm ( 1:1:1 ) : Experimental : Endostar -Continued Pumping into+Gemcitabine-Carboplatin ( GC ) , Active Comparator : Endostar -injecting +Gemcitabine-Carboplatin ( GC ) , Active Comparator : Gemcitabine-Carboplatin ( GC ) ,</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histologically cytologically diagnose NSCLC ; 2. primary treatment , inoperable stage III/IV NSCLC ; 3 . Age 1870years ; Gender Not Required ; 4 . Adequate hematologic , renal , hepatic function , Specific index follow : liver function : SBilirubin ≤1.5 ULN ; Transaminase≤2 ULN . renal function : SCreatinine ≤1.2 ULN ; blood urea nitrogen ≤1.2 ULN . ULN : upper normal limit . Marrow Hemopoietic Function : WBC≥4.0×10^9/l , ANC≥2.0×10^9/l platelet count ≥100×10^9/l , Hb≥100 g/l ; 5 . ECOG PS 02 , Life expectancy ≥ 3 month ; endure two cycle chemotherapy ; 6 . The patient explicit lung tumor lesion lesion measurable ; ( According standard RECIST1.1 , least one accurately measurable lesion large diameter ≥ 10mm spiral CT , MRI ) ; 7 . No history serious drug allergy ; 8 . Informed consent obtain treatment . 1 . Symptomatic brain metastasis cognitive disorder , bone metastasis complication ; 2 . Major organ dysfunction Serious Heart Disease ( congestive heartfailure , incontrollable highrisk arrhythmia , unstable angina , valvular disease , myocardial infarct Resistant hypertension , ) ; 3 . Serious complication investigator consider unsuited enrolling ; 4 . Pregnant lactating woman ; 5 . Allergic research drug ; 6. participate experimental trial receive treatment four week ; 7 . The position observe curative effect radiotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Endostar</keyword>
	<keyword>Continued Pumping</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Carboplatin</keyword>
</DOC>